Apr 28, 2023 8:30am EDT RenovoRx to Participate in the Aegis Capital Virtual Conference on May 3, 2023
Apr 27, 2023 8:30am EDT RenovoRx Appoints Former Chief Medical Officer of Schering-Plough, Robert J. Spiegel, MD, FACP, to Board of Directors
Apr 14, 2023 8:30am EDT RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study at American Association for Cancer Research Annual Meeting Underway in Orlando, Florida
Apr 11, 2023 8:30am EDT RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations
Mar 30, 2023 12:20pm EDT RenovoRx, Inc. Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Mar 30, 2023 8:30am EDT RenovoRx Announces Positive New Data from Phase III Clinical Trial Interim Analysis: 60% Survival Benefit and Fewer Side Effects than Systemic Chemotherapy
Mar 08, 2023 8:30am EST RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGem™ as a Treatment Option for Locally Advanced Pancreatic Cancer
Mar 02, 2023 8:30am EST RenovoRx Reports Full Year 2022 Financial Results and Achievement of Important Phase III Clinical Study Milestone
